Page last updated: 2024-11-04

ro 48-8071

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ro 48-8071: a cholesterol synthesis inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Ro 48-8071 : An aromatic ketone that is 2-fluoro-4'-bromobenzophenone in which the hydrogen at position 4 (meta to the fluoro group) is replaced by a 6-[methyl(prop-2-en-1-yl)amino]hexyl}oxy group. An inhibitor of lanosterol synthase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1949
CHEMBL ID304858
CHEBI ID101064
SCHEMBL ID3674881
MeSH IDM0275703

Synonyms (44)

Synonym
ro-48-8071
ro 48-8071
methanone, (4-bromophenyl)[2-fluoro-4-[[6-(methyl-2-propenylamino)hexyl]oxy]phenyl]-,(2e)-2-butenedioate
[4-[6-[allyl(methyl)amino]hexoxy]-2-fluoro-phenyl]-(4-bromophenyl)methanone
[4-({6-[allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone
r048-8071
NCGC00165878-01
DB02016
1GSZ ,
161582-11-2
bdbm50128065
n-allyl-6-(4-(4-bromobenzoyl)-3-fluorophenoxy)-n-methylhexan-1-aminium
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-bromo-phenyl)-methanone
CHEMBL304858 ,
(4-bromophenyl)-[2-fluoro-4-[6-[methyl(prop-2-enyl)amino]hexoxy]phenyl]methanone
CHEBI:101064
(4-bromophenyl)[2-fluoro-4-({6-[methyl(prop-2-en-1-yl)amino]hexyl}oxy)phenyl]methanone
NCGC00165878-02
unii-ydr69x9q9m
(4'-(6-allylmethylaminohexyloxy)-2'-fluorophenyl)-4-(4-bromophenyl)methanone fumarate
ydr69x9q9m ,
methanone, (4-bromophenyl)(2-fluoro-4-((6-(methyl-2-propenylamino)hexyl)oxy)phenyl)-
(4-bromophenyl)-[2-fluoro-4-[6-(methyl-prop-2-enylamino)hexoxy]phenyl]methanone
compound 2 [pmid: 22533316]
gtpl6710
AKOS025294639
SCHEMBL3674881
CS-3518
(4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl)-(4-bromo-phenyl)-methanone
CMYCCJYVZIMDFU-UHFFFAOYSA-N
[4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl]-(4-bromo-phenyl)-methanone
HY-18630
HMS3649J22
J-009841
ro48-8071
Q27088590
sr-01000946731
SR-01000946731-1
A14203
ro 488071; ro488071; ro-488071; ro 488071; ro-488071
BCP30557
HMS3743C21
DTXSID90870077
methanone, (4-bromophenyl)[2-fluoro-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]phenyl]-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 5.4.99.7 (lanosterol synthase) inhibitorAn EC 5.4.99.* (intramolecular transferase transferring other groups) inhibitor that interferes with the action of lanosterol synthase (EC 5.4.99.7).
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
monofluorobenzenesAny member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent.
bromobenzenesA member of the class of benzenes that is benzene substituted by at least one bromo group.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
olefinic compoundAny organic molecular entity that contains at least one C=C bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency25.11895.623417.292931.6228AID485281
phosphopantetheinyl transferaseBacillus subtilisPotency11.22020.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency5.01190.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency12.58930.00018.4406100.0000AID720580
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Squalene--hopene cyclaseAlicyclobacillus acidocaldarius subsp. acidocaldarius DSM 446IC50 (µMol)0.06000.06003.53007.0000AID204670
Lanosterol synthaseHomo sapiens (human)IC50 (µMol)0.07930.00651.73966.3100AID1375929; AID298048; AID371186
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)0.00650.00051.33138.0000AID298048
Monoglyceride lipaseRattus norvegicus (Norway rat)IC50 (µMol)0.00650.00650.13900.3150AID298048
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
steroid biosynthetic processLanosterol synthaseHomo sapiens (human)
cholesterol biosynthetic processLanosterol synthaseHomo sapiens (human)
triterpenoid biosynthetic processLanosterol synthaseHomo sapiens (human)
regulation of protein stabilityLanosterol synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
lanosterol synthase activityLanosterol synthaseHomo sapiens (human)
protein bindingLanosterol synthaseHomo sapiens (human)
acylglycerol lipase activityMonoglyceride lipaseRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneLanosterol synthaseHomo sapiens (human)
lipid dropletLanosterol synthaseHomo sapiens (human)
membraneLanosterol synthaseHomo sapiens (human)
lipid dropletLanosterol synthaseHomo sapiens (human)
lipid dropletMonoglyceride lipaseRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1375930Selectivity ratio of IC50 for human C-terminal His6-tagged OSC to IC50 for Trypanosoma cruzi strain CL Brener C-terminal His6-tagged OSC2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
NMR Biochemical Assay for Oxidosqualene Cyclase: Evaluation of Inhibitor Activities on Trypanosoma cruzi and Human Enzymes.
AID204670Inhibitory activity against squalene hopene cyclase from Alicyclobacillus acidocaldarius2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Binding structures and potencies of oxidosqualene cyclase inhibitors with the homologous squalene-hopene cyclase.
AID1375928Inhibition of Trypanosoma cruzi strain CL Brener C-terminal His6-tagged OSC expressed in Pichia pastoris GS115 using 2,3-oxidosqualene as substrate after 20 mins by 1H NMR method2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
NMR Biochemical Assay for Oxidosqualene Cyclase: Evaluation of Inhibitor Activities on Trypanosoma cruzi and Human Enzymes.
AID1277204Cytotoxicity against human HL60 cells after 24 hrs by MTT assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Arylpiperidines as a new class of oxidosqualene cyclase inhibitors.
AID745339Cytotoxicity against human HL60 cells after 24 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 63Aminopropylindenes derived from Grundmann's ketone as a novel chemotype of oxidosqualene cyclase inhibitors.
AID1277202Inhibition of total cholesterol biosynthesis in human HL60 cells assessed as incorporation of 2-13C-acetate by GC-MS analysis2016European journal of medicinal chemistry, Feb-15, Volume: 109Arylpiperidines as a new class of oxidosqualene cyclase inhibitors.
AID1375931Antiparasitic activity against epimastigote stage of Trypanosoma cruzi Tulahuen assessed as inhibition of parasite proliferation after 48 hrs by Alamar Blue assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
NMR Biochemical Assay for Oxidosqualene Cyclase: Evaluation of Inhibitor Activities on Trypanosoma cruzi and Human Enzymes.
AID1375929Inhibition of human C-terminal His6-tagged OSC expressed in Pichia pastoris GS115 using 2,3-oxidosqualene as substrate after 90 mins by 1H NMR method2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
NMR Biochemical Assay for Oxidosqualene Cyclase: Evaluation of Inhibitor Activities on Trypanosoma cruzi and Human Enzymes.
AID745338Inhibition of cholesterol biosynthesis in human HL60 cells at 1 uM2013European journal of medicinal chemistry, May, Volume: 63Aminopropylindenes derived from Grundmann's ketone as a novel chemotype of oxidosqualene cyclase inhibitors.
AID371186Inhibition of oxidosqualene cyclase2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
GRIND-based 3D-QSAR to predict inhibitory activity for similar enzymes, OSC and SHC.
AID151650Inhibitory activity against Oxidosqualene-lanosterol cyclase from human liver microsomes2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Binding structures and potencies of oxidosqualene cyclase inhibitors with the homologous squalene-hopene cyclase.
AID1277211Inhibition of Saccharomyces cerevisiae OSC expressed in recombinant Saccharomyces cerevisiae SMY8 using [14C]-(3S)-2,3-oxidosqualene as substrate2016European journal of medicinal chemistry, Feb-15, Volume: 109Arylpiperidines as a new class of oxidosqualene cyclase inhibitors.
AID1277201Inhibition of OSC in human HL60 cells assessed as accumulation of 2,3-oxidosqualene by GC-MS method2016European journal of medicinal chemistry, Feb-15, Volume: 109Arylpiperidines as a new class of oxidosqualene cyclase inhibitors.
AID371185Inhibition of squalene-hopene cyclase2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
GRIND-based 3D-QSAR to predict inhibitory activity for similar enzymes, OSC and SHC.
AID298048Inhibition of oxidosqualene cyclase2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Influence of conformation on GRIND-based three-dimensional quantitative structure-activity relationship (3D-QSAR).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (12.50)18.2507
2000's13 (40.63)29.6817
2010's13 (40.63)24.3611
2020's2 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.58 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]